Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis

Genome Medicine

Volumn 6, Issue 12, 2014, Pages

  Liu, Zhichao ^a   Borlak, Jürgen ^b   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR; UBIQUITIN;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CYSTIC FIBROSIS; DRUG REPOSITIONING; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN TISSUE; PATHOGENESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RESPIRATORY EPITHELIUM;

EID: 84927780905     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-014-0094-2     Document Type: Article

References (103)

1. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18:509-519. 10.1038/nm.2715, 22481418.
2. Storey S, Wald G. Novel agents in cystic fibrosis. Nat Rev Drug Discov 2008, 7:555-556. 10.1038/nrd2603, 18591977.
3. Drug bests cystic-fibrosis mutation. http://www.nature.com/news/drug-bests-cystic-fibrosis-mutation-1.9983
4. Are we entering the age of the $1 million medicine? http://www.foxnews.com/health/2013/01/03/are-entering-age-1-million-medicine/
5. Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform 2011, 12:346-356. 10.1093/bib/bbr021, 21504985.
6. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011, 16:298-310. 10.1016/j.drudis.2011.02.016, 21376136.
7. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007, 28:331-346. 10.1016/j.ccm.2007.02.002, 17467552.
8. Kraynack NC, Corey DA, Elmer HL, Kelley TJ. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002, 283:L604-L611. 12169580.
9. BalfourLynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996, 75:319-322. 10.1136/adc.75.4.319.
10. Kharitonov SA, Yates D, Robbins RA, Logansinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994, 343:133-135. 10.1016/S0140-6736(94)90931-8, 7904001.
11. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Network motifs: simple building blocks of complex networks. Science 2002, 298:824-827. 10.1126/science.298.5594.824, 12399590.
12. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010, 6:40-49. 10.1038/nrrheum.2009.237, 20046205.
13. Taylor RC, Acquaah-Mensah G, Singhal M, Malhotra D, Biswal S. Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress. PLoS Comput Biol 2008, 4:e1000166. 10.1371/journal.pcbi.1000166, 18769717.
14. Guo A-Y, Sun J, Jia P, Zhao Z. A Novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol 2010, 4:10. 10.1186/1752-0509-4-10, 20156358.
15. Afshar AS, Xu J, Goutsias J. Integrative Identification of Deregulated MiRNA/TF-Mediated Gene Regulatory Loops and Networks in Prostate Cancer. PLoS ONE 2014, 9:e100806. 10.1371/journal.pone.0100806, 24968068.
16. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007, 8:93-103. 10.1038/nrg1990, 17230196.
17. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008, 9:219-230. 10.1038/nrm2347, 18270516.
18. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269. 10.1038/nrc1840, 16557279.
19. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261. 10.1073/pnas.0510565103, 16461460.
20. Angerstein C, Hecker M, Paap BK, Koczan D, Thamilarasan M, Thiesen HJ, Zettl UK. Integration of microRNA databases to study microRNAs associated with multiple sclerosis. Mol Neurobiol 2012, 45:520-535. 10.1007/s12035-012-8270-0, 22549745.
21. Ling HY, Ou HS, Feng SD, Zhang XY, Tuo QH, Chen LX, Zhu BY, Gao ZP, Tang CK, Yin WD, Zhang L, Liao DF. CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3 T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009, 36:e32-e39. 10.1111/j.1440-1681.2009.05207.x, 19473196.
22. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z. Hood LE 2009, Galas DJ, Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci.
23. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 2010, 3:251-255. 10.1007/s12265-010-9169-7, 20560046.
24. Hassan F, Nuovo GJ, Crawford M, Boyaka PN, Kirkby S, Nana-Sinkam SP, Cormet-Boyaka E. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One 2012, 7:e50837. 10.1371/journal.pone.0050837, 23226399.
25. Ramachandran S, Karp PH, Jiang P, Ostedgaard LS, Walz AE, Fisher JT, Keshavjee S, Lennox KA, Jacobi AM, Rose SD, Behlke MA, Welsh MJ, Xing Y, McCray PB. A microRNA network regulates expression and biosynthesis of wild-type and Delta F508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A 2012, 109:13362-13367. 10.1073/pnas.1210906109, 22853952.
26. Megiorni F, Cialfi S, Dominici C, Quattrucci S, Pizzuti A. Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding. PLoS One 2011, 6:e26601. 10.1371/journal.pone.0026601, 22028919.
27. Gillen AE, Gosalia N, Leir SH. Harris A: microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem J 2011, 438:25-32. 10.1042/BJ20110672, 21689072.
28. Xu W, Hui C, Yu SSB, Jing C, Chan HC. MicroRNAs and cystic fibrosis - an epigenetic perspective. Cell Biol Int 2011, 35:463-466. 10.1042/CBI20100664, 21476987.
29. Collison A, Herbert C, Siegle J, Mattes J, Foster P, Kumar R. Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target. BMC Pulmonary Medicine 2011, 11:29. 10.1186/1471-2466-11-29, 21605405.
30. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet 2009, 10:252-263. 10.1038/nrg2538, 19274049.
31. Hobert O. Gene regulation by transcription factors and microRNAs. Science 2008, 319:1785-1786. 10.1126/science.1151651, 18369135.
32. Genetic Association Database. http://geneticassociationdb.nih.gov/
33. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet 2004, 36:431-432. 10.1038/ng0504-431, 15118671.
34. Ayme S, Schmidtke J. Networking for rare diseases: a necessity for Europe. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007, 50:1477-1483. 10.1007/s00103-007-0381-9, 18026888.
35. Orphadata. http://www.orphadata.org/cgi-bin/index.php
36. Online Mendelian Inheritance in Man (OMIM). http://www.omim.org/
37. McKusick VA. Mendelian inheritance in man and its online version, OMIM. Am J Hum Genet 2007, 80:588-604. 10.1086/514346, 17357067.
38. Functional Disease Ontology Annotations (FunDO). http://django.nubic.northwestern.edu/fundo/
39. Schriml LM, Arze C, Nadendla S, Chang YWW, Mazaitis M, Felix V, Feng G, Kibbe WA. Disease Ontology: a backbone for disease semantic integration. Nucleic Acids Res 2012, 40:D940-D946. 10.1093/nar/gkr972, 22080554.
40. Oglesby IK, Bray IM, Chotirmall SH, Stallings RL, O' Neill SJ, McElvaney NG, Greene CM. miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression. J Immunol 2010, 184:1702-1709. 10.4049/jimmunol.0902669, 20083669.
41. Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB, Biswas R. Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem 2011, 286:11604-11615. 10.1074/jbc. M110.198390, 21282106.
42. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798. 10.1016/S0092-8674(03)01018-3, 14697198.
43. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008, 455:64-U38. 10.1038/nature07242, 18668037.
44. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63. 10.1038/nature07228, 18668040.
45. Sun JC, Gong X, Purow B, Zhao ZM. Uncovering microRNA and transcription factor mediated regulatory networks in glioblastoma. PLoS Comput Biol 2012, 8:e1002488. 10.1371/journal.pcbi.1002488, 22829753.
46. Yang J-H, Li J-H, Jiang S, Zhou H, Qu L-H. ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 2013, 41:D177-187. 10.1093/nar/gks1060, 23161675.
47. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Holko M, Ayanbule O, Yefanov A, Soboleva A. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011, 39:D1005-D1010. 10.1093/nar/gkq1184, 21097893.
48. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011, 9:e1001046. 10.1371/journal.pbio.1001046.
49. Negre N, Brown CD, Ma LJ, Bristow CA, Miller SW, Wagner U, Kheradpour P, Eaton ML, Loriaux P, Sealfon R, Li Z, Ishii H, Spokony RF, Chen J, Hwang L, Cheng C, Auburn RP, Davis MB, Domanus M, Shah PK, Morrison CA, Zieba J, Suchy S, Senderowicz L, Victorsen A, Bild NA, Grundstad AJ, Hanley D, MacAlpine DM, Mannervik M, et al. A cis-regulatory map of the Drosophila genome. Nature 2011, 471:527-531. 10.1038/nature09990, 21430782.
50. Gerstein MB, Lu ZJ, Van Nostrand EL, Cheng C, Arshinoff BI, Liu T, Yip KY, Robilotto R, Rechtsteiner A, Ikegami K, Alves P, Chateigner A, Perry M, Morris M, Auerbach RK, Feng X, Leng J, Vielle A, Niu W, Rhrissorrakrai K, Agarwal A, Alexander RP, Barber G, Brdlik CM, Brennan J, Brouillet JJ, Carr A, Cheung MS, Clawson H, Contrino S, et al. Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science 2010, 330:1775-1787. 10.1126/science.1196914, 21177976.
51. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, von Mering C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, 39:D561-D568. 10.1093/nar/gkq973, 21045058.
52. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004, 18:1165-1178. 10.1101/gad.1184704, 15131085.
53. Enright A, John B, Gaul U, Tuschl T, Sander C, Marks D. MicroRNA targets in Drosophila. Genome Biol 2003, 5:R1. 10.1186/gb-2003-5-1-r1, 14709173.
54. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 2008, 24:325-332. 10.1093/bioinformatics/btm595, 18048393.
55. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011, 44:839-847. 10.1016/j.jbi.2011.05.002, 21605702.
56. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517. 10.1261/rna.5248604, 15383676.
57. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500. 10.1038/ng1536, 15806104.
58. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007, 39:1278-1284. 10.1038/ng2135, 17893677.
59. Miranda KC, Huynh T, Tay Y, Ang Y-S, Tam W-L, Thomson AM, Lim B, Rigoutsos I. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217. 10.1016/j.cell.2006.07.031, 16990141.
60. Grimson A, Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91-105. 10.1016/j.molcel.2007.06.017, 17612493.
61. Liu X, Wang S, Meng F, Wang J, Zhang Y, Dai E, Yu X, Li X, Jiang W. SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression. Bioinformatics 2013, 29:409-411. 10.1093/bioinformatics/bts698, 23220571.
62. Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 2014, 15:648-659. 10.1093/bib/bbs082, 23376192.
63. Kamanu TKK, Radovanovic A, Archer JAC, Bajic VB. Exploration of miRNA families for hypotheses generation. Sci Rep 2013, 3:2940. 10.1038/srep02940, 24126940.
64. Kimura T, Kawabe H, Jiang C, Zhang WB, Xiang YY, Lu C, Salter MW, Brose N, Lu WY, Rotin D. Deletion of the ubiquitin ligase Nedd4L in lung epithelia causes cystic fibrosis-like disease. Proc Natl Acad Sci U S A 2011, 108:3216-3221. 10.1073/pnas.1010334108, 21300902.
65. Kelley TJ, Elmer HL, Corey DA. Reduced Smad3 protein expression and altered transforming growth factor-beta 1-mediated signaling in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2001, 25:732-738. 10.1165/ajrcmb.25.6.4574, 11726399.
66. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000, 20:2423-2435. 10.1128/MCB.20.7.2423-2435.2000, 10713166.
67. Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci 2011, 108:18843-18848. 10.1073/pnas.1105787108, 21976485.
68. Bridges N. Diabetes in cystic fibrosis. Paediatr Respir Rev 2013, Suppl 1:16-18. 10.1016/j.prrv.2013.02.002.
69. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004, 85:47-64. 10.1111/j.0959-9673.2004.00377.x, 15154911.
70. Howe KL, Wang A, Hunter MM, Stanton BA, McKay DM. TGF beta down-regulation of the CFTR: a means to limit epithelial chloride secretion. Exp Cell Res 2004, 298:473-484. 10.1016/j.yexcr.2004.04.026, 15265695.
71. Fo J, Bernard A, Hermans C, Dom G, Terryn S, Leal T, Lebecque P, Cassiman J-J, Scholte BJ, de Jonge HR, Courtoy PJ, Devuyst O. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 2007, 18:707-718. 10.1681/ASN.2006030269.
72. PharmGKB. http://www.pharmgkb.org/
73. DrugBank. http://www.drugbank.ca/
74. Smith LK, Shah RR, Cidlowski JA. Glucocorticoids modulate microRNA expression and processing during lymphocyte apoptosis. J Biol Chem 2010, 285:36698-36708. 10.1074/jbc. M110.162123, 20847043.
75. Kino T, Nordeen SK, Chrousos GP. Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 1999, 70:15-25. 10.1016/S0960-0760(99)00100-4, 10528999.
76. Rebeyrol C, Saint-Criq V, Guillot LC, Riffault L, Corvol H, Chadelat K, Ray DW, Clement A, Tabary O, Le Rouzic P. Glucocorticoids reduce inflammation in cystic fibrosis bronchial epithelial cells. Cell Signal 2012, 24:1093-1099. 10.1016/j.cellsig.2012.01.005, 22285804.
77. Rossi L, Castro M, D'Orio F, Damonte G, Serafini S, Bigi L, Panzani I, Novelli G, Dallapiccola B, Panunzi S, Di Carlo P, Bella S, Magnani M. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cell Mol Dis 2004, 33:57-63. 10.1016/j.bcmd.2004.04.004.
78. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Doring G, Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391. 10.1038/nm1748, 18376404.
79. Pier GB. Dropping acid to help cystic fibrosis. Nat Med 2008, 14:367-369. 10.1038/nm0408-367, 18391932.
80. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39. 10.1038/35036052, 11413487.
81. Furberg C, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001, 2:205-207. 10.1186/CVM-2-5-205, 11806796.
82. Jones A, Helm J. Emerging treatments in cystic fibrosis. Drugs 2009, 69:1903-1910. 10.2165/11318500-000000000-00000, 19747007.
83. Fdr B, Verrier B, Chang X-B, Riordan JR, Hanrahan JW. cAMP- and Ca2 + -independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J Biol Chem 1996, 271:16171-16179. 10.1074/jbc.271.27.16171.
84. Becq F, Jensen TJ, Chang XB, Savoia A, Rommens JM, Tsui LC, Buchwald M, Riordan JR, Hanrahan JW. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci 1994, 91:9160-9164. 10.1073/pnas.91.19.9160, 7522329.
85. Mun EC, Mayol JM, Riegler M, O'Brien TC, Farokhzad OC, Song JC, Pothoulakis C, Hrnjez BJ, Matthews JB. Levamisole inhibits intestinal Clâ ' secretion via basolateral K + channel blockade. Gastroenterology 1998, 114:1257-1267. 10.1016/S0016-5085(98)70432-9, 9609763.
86. Innis SM, Davidson AGF, Bay BN, Slack PJ, Hasman D. Plasma choline depletion is associated with decreased peripheral blood leukocyte acetylcholine in children with cystic fibrosis. Am J Clin Nutr 2011, 93:564-568. 10.3945/ajcn.110.005413, 21228267.
87. Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, Glass CK. Pharmacological correction of a defect in PPAR-[gamma] signaling ameliorates disease severity in Cftr-deficient mice. Nat Med 2010, 16:313-318. 10.1038/nm.2101, 20154695.
88. Henney JE. Withdrawal of troglitazone and cisapride. JAMA 2000, 283:2228. 10.1001/jama.283.17.2228-JFD00003-2-1.
89. Faivre L, Bonnefont JP, Lyonnet S, Munnich A, Vekemans M. Improvement of cystic fibrosis using antitumoral drugs: a hypothesis. Med Hypotheses 2000, 54:580-581. 10.1054/mehy.1999.0899, 10859642.
90. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?. Lancet 1997, 350:711-712. 10.1016/S0140-6736(05)63510-6, 9291908.
91. Jiang W, Chen X, Liao M, Li W, Lian B, Wang L, Meng F, Liu X, Chen X, Jin Y, Li X. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep 2012, 2:282. 22355792.
92. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E. TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006, 34:D108-D110. 10.1093/nar/gkj143, 16381825.
93. Blancafort P, Segal DJ, Barbas CF. Designing transcription factor architectures for drug discovery. Mol Pharmacol 2004, 66:1361-1371. 10.1124/mol.104.002758, 15340042.
94. Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol 2013, 160:465-476. 10.1111/bjh.12164, 23252346.
95. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16:1053-1068. 10.1038/sj.leu.2402482, 12040437.
96. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-[kappa]B is the answer - role of Rel//NF-[kappa]B in the regulation of apoptosis. Oncogene 2003, 22:8961-8982. 10.1038/sj.onc.1207230, 14663476.
97. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002, 64:883-888. 10.1016/S0006-2952(02)01154-1, 12213582.
98. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. New Engl J Med 1995, 332:848-854. 10.1056/NEJM199503303321303, 7503838.
99. Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian Safety and Effectiveness Trial. J Pediatr 2007, 151:249-254. 10.1016/j.jpeds.2007.04.009, 17719932.
100. Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W, Tong W. In silico drug repositioning - what we need to know. Drug Discov Today 2013, 18:110-115. 10.1016/j.drudis.2012.08.005, 22935104.
101. FDA Adverse Event Reporting System (FAERS). http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/default.htm
102. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System - a national resource for evidence development. New Engl J Med 2011, 364:498-499. 10.1056/NEJMp1014427, 21226658.
103. Hartman M, Martin A, McDonnell P, Catlin A. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998. Health Aff 2009, 28:246-261. 10.1377/hlthaff.28.1.246.